natgillin/translations-raw huggingface dataset:
if you are a child (below 18 years old) if you have an autoimmune disease (disease arising from or directed against your own tissues), including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren’s syndrome and dermatomyositis/ polymyositis.
če ste otrok (če ste stari manj kot 18 let); če imate avtoimunsko bolezen (bolezen, ki izhaja iz vaših lastnih tkiv ali deluje proti njim), vključno z reumatoidnim artritisom, sistemskim lupusom eritematozusom, sklerodermo, Sjögrenovim sindromom in dermatomiositisom/polimiositisom;
if you are a child (less than 18 years of age), this medicine is not appropriate for you.
če ste otrok (mlajši od 18 let), ker to zdravilo ni primerno za vas.
if you are a child below the age of 18
če ste mlajši od 18 let
If you are a child or adolescent under 18 years old.
Če ste otrok ali mladostnik, mlajši od 18 let.
if you are a child that has already stopped growing;
če ste otrok, ki je že prenehal rasti.
if you are a diabetic or have an illness known as ‘diabetic retinopathy’ (problems with the blood vessels in the eye caused by diabetes)
če ste sladkorni bolnik ali imate diabetično retinopatijo (težave z ožiljem v očesu, ki so posledica sladkorne bolezni),
if you are a girl or a woman of childbearing age who is taking ribavirin: you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped.
Test nosečnosti mora biti pri vas negativen pred zdravljenjem, vsak mesec med zdravljenjem in še
if you are a girl or a woman of childbearing age who is taking ribavirin: you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped.
Test nosečnosti mora biti pri vas negativen pred zdravljenjem, vsak mesec med zdravljenjem in še mesece po zaključku zdravljenja.
If you are a HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of this medicine and peginterferon alfa may increase your risk of worsening liver function (combined anti- retroviral therapy (cART)) and increase your risk of lactic acidosis, liver failure and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets) (NRTI).
Če ste odrasel bolnik, ki je sočasno okužen z virusoma HCV in HIV in prejema zdravljenje proti okužbi z virusom HIV, lahko dodatek tega zdravila in peginterferona alfa-2b k terapiji poveča tveganje za poslabšanje delovanja jeter (kombinirana protiretrovirusna terapija (cART)) in tudi tveganje za nastanek laktacidoze, jetrne odpovedi in krvnih motenj (npr. zmanjšanje števila rdečih krvnih celic, ki prenašajo kisik po telesu, zmanjšanje števila določenih belih krvnih celic, ki služijo za boj proti okužbam, in zmanjšanje števila krvnih celic, ki so odgovorne za strjevanje krvi in jim pravimo trombociti) (NRTI).
If you are a HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of this medicine and peginterferon alfa-2b may increase your risk of worsening liver function combined anti- retroviral therapy (cART) and increase your risk of lactic acidosis, liver failure, and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets) (NRTI).
Če ste odrasel bolnik, ki je sočasno okužen z virusoma HCV in HIV in prejema terapijo proti virusu HIV, lahko dodatek tega zdravila in peginterferona alfa-2b k terapiji poveča tveganje za motnje delovanja jeter, kombinirana protiretrovirusna terapija (cART) in tudi tveganje za nastanek laktacidoze, jetrne odpovedi in krvnih motenj (npr. zmanjšanje števila rdečih krvničk, ki prenašajo kisik po telesu, zmanjšanje števila določenih belih krvničk, ki služijo za boj proti okužbam, in zmanjšanje števila krvničk, ki so odgovorne za strjevanje krvi in jim pravimo trombociti) (NRTI).
If you are a HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of this medicine and peginterferon alfa-2b may increase your risk of worsening liver function highly active anti-retroviral therapy (HAART) and increase your risk of lactic acidosis, liver failure, and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets) (NRTI).
Če ste odrasli bolnik, ki je sočasno okužen z virusoma HCV in HIV in prejema terapijo proti virusu HIV, lahko dodatek tega zdravila in peginterferona alfa-2b k terapiji poveča tveganje za motnje delovanja jeter, močno aktivna protiretrovirusna terapija (HAART) in tudi tveganje za nastanek laktacidoze, jetrne odpovedi in krvnih motenj (npr. zmanjšanje števila rdečih krvničk, ki prenašajo kisik po telesu, zmanjšanje števila določenih belih krvničk, ki služijo za boj proti okužbam, in zmanjšanje števila krvničk, ki so odgovorne za strjevanje krvi in jim pravimo trombociti) (NRTI).
if you are a heavy drinker of alcohol – if you regularly drink a lot, or if you have occasional sessions of heavy drinking (binge drinking)
če prekomerno uživate alkoholne pijače – redno ali občasno (npr. na zabavah) prekomerno uživanje alkoholnih pijač.
If you are a male patient, you a or your partner must use an effective contraceptive during the time you are taking ribavirin and for 7 months after stopping treatment.
Če ste moški, morate vi ali vaša partnerka uporabljati učinkovito kontracepcijo v času jemanja ribavirina in še 7 mesecev po zaključku zdravljenja.
If you are a man being treated with Docetaxel Winthrop you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.
Če ste moški, ki se zdravi z zdravilom Docetaxel Winthrop je priporočljivo, da ne zaplodite otroka me dzdravljenjem in v obdobju 6 mesecev po koncu zdravljenja ter da pred začetkom zdravljenja poiščete nasvet glede ohranitve sperme, ker docetaksel lahko prizadene moško plodnost.
If you are a man being treated with Docetaxel Winthrop you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.
Če ste moški, ki se zdravi z zdravilom Docetaxel Winthrop je priporočljivo, da ne zaplodite otroka med zdravljenjem in v obdobju 6 mesecev po koncu zdravljenja ter da pred začetkom zdravljenja poiščete nasvet glede ohranitve sperme, ker docetaksel lahko prizadene moško plodnost.
if you are a man who is taking ribavirin: do not have sex with a pregnant woman unless you use a condom.
Ne smete imeti spolnih odnosov z nosečo žensko brez uporabe kondoma.
if you are a man with: testicular failure that is not treatable.
če ste moški: z odpovedjo testisov, ki je ni mogoče zdraviti.
If you are a man, your female partner must not become pregnant during your treatment and for several months afterwards.
Če ste moški, vaša partnerka ne sme zanositi v času, ko vi jemljete zdravila in še nekaj mesecev po zaključku zdravljenja z njimi.
If you are a man: with damaged testicles that cannot be healed.
Če ste moški: z nepopravljivo poškodbo testisov.
If you are a newly-diagnosed patient (glioblastoma multiforme) you may be receiving Temozolomide Hexal for 42 days in combination with radiotherapy.
Če so vam bolezen (multiformni glioblastom) ugotovili na novo, boste morda zdravilo Temozolomid Hexal prejemali 42 dni v kombinaciji z radioterapijo.
If you are a newly-diagnosed patient (glioblastoma multiforme) you may be receiving Temozolomide Sandoz for 42 days in combination with radiotherapy.
Če so vam bolezen (multiformni glioblastom) ugotovili na novo, boste morda zdravilo Temozolomid Sandoz prejemali 42 dni v kombinaciji z radioterapijo.
If you are a newly-diagnosed patient, treatment will occur in two phases:
Če so vam bolezen diagnosticirali na novo, bo zdravljenje potekalo v dveh fazah:
If you are a newly-diagnosed patient, treatment will occur in two phases:
Če ste na novo diagnosticiran bolnik, bo zdravljenje potekalo v dveh fazah:
If you are a newly-diagnosed patient, treatment will occur in two phases:
Če ste na novo diagnosticiran bolnik, bo zdravljenje potekalo v dveh obdobjih:
If you are a patient with chronic kidney disease and anemia treated with an ESA and are also a cancer patient you should be aware that ESAs, might have a negative impact on your condition.
Če za zdravljenje kronične bolezni ledvic in anemije prejemate zdravila za spodbujanje eritropoeze in imate obenem tudi raka, bodite pozorni na podatek, da lahko zdravila za spodbujanje eritropoeze negativno vplivajo na vašo bolezen.
If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
Če ste bolnik s kronično odpovedjo ledvic in še posebej, če se na zdravilo Aranesp ne odzovete primerno, vam bo zdravnik preverjal vaš odmerek zdravila Aranesp, ker lahko ponavljajoče se povečevanje odmerka zdravila Aranesp, če se na zdravilo ne odzovete, poveča tveganje za težave s srcem ali ožiljem in vam lahko poveča tveganje za srčni infarkt, možgansko kap in smrt.
If you are a patient with chronic renal failure, and particularly if you do not respond properly to Retacrit, your doctor will check your dose of Retacrit because repeatedly increasing your dose of Retacrit if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
Če ste bolnik s kronično ledvično okvaro, zlasti če se na zdravilo Retacrit ne odzivate ustrezno, bo zdravnik spremljal vaš odmerek zdravila Retacrit, ker ponavljajoče se zviševanje odmerka zdravila Retacrit, če se na zdravljenje ne odzivate, lahko poveča tveganje za težave s srcem ali krvnimi žilami in lahko poveč tveganje za srčni infarkt, možgansko kap in smrt.
If you are a patient with chronic renal failure, and particularly if you do not respond properly to Silapo, your doctor will check your dose of Silapo because repeatedly increasing your dose of Silapo if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
Če ste bolnik s kronično ledvično okvaro; zlasti, če se na zdravilo Silapo ne odzivate ustrezno, bo zdravnik spremljal vaš odmerek zdravila Silapo, ker ponavljajoče se zviševanje odmerka zdravila Silapo, če se na zdravljenje ne odzivate, lahko poveča tveganje za težave s srcem ali krvnimi žilami in lahko poveča tveganje za srčni infarkt, možgansko kap in smrt.
If you are a patient with chronic renal failure, your doctor will check that a particular blood parameter (haemoglobin) does not exceed a defined threshold.
Če imate kronično ledvično odpoved, bo zdravnik preveril, da poseben krvni parameter (hemoglobin) ne presega opredeljene meje.
If you are a patient with hepatitis C and you receive interferon and ribavirin you should discuss this with your doctor because a combination of ESAs with interferon and ribavirin has lead to a loss of effect and development of PRCA, a severe form of anemia, in rare cases.
Če imate hepatitis C in prejemate interferon ter ribavirin se morate o tem pogovoriti s svojim zdravnikom, saj kombinacija zdravil za spodbujanje eritropoeze z interferonom in ribavirinom lahko v redkih primerih privede do izgube učinka in razvoja čiste aplazije rdečih krvnih celic, hude oblike anemije.
If you are a patient with hepatitis C and you receive interferon and ribavirin, you should discuss this with your doctor because a combination of epoetin alfa with interferon and ribavirin has led to a loss of effect and development of a condition called pure red cell aplasia (PRCA), a severe form of anaemia, in rare cases.
Če ste bolnik s hepatitisom C in prejemate interferon in ribavirin, se morate o tem pogovoriti s svojim zdravnikom, saj je kombinacija epoetina alfa z interferonom in ribavirinom v redkih primerih povzročila izgubo učinka in razvoj stanja, imenovanega čista aplazija rdečih krvnih celic (PRCA – pure red cell aplasia), ki je resna oblika anemije.
If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome (MDS)).
Če ste bolnik s hudo kronično nevtropenijo, lahko pri vas obstaja tveganje za nastanek krvnega raka (levkemija, mielodisplastični sindrom (MDS – myelodisplastic syndrome)).
If you are a pregnant or breast feeding, think you may be pregnant or are planning to have a baby, talk to your doctor.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete nosečnost, se posvetujte z zdravnikom.
If you are a sexually active woman, you should use an effective method of contraception during treatment.
Če ste spolno aktivna ženska, morate med zdravljenjem uporabljati učinkovito metodo kontracepcije.
if you are a smoker if you have advanced chronic liver disease
če kadite, če imate napredovalo kronično bolezen jeter.
if you are a woman able to have children and not using reliable contraception;
če ste ženska v rodni dobi in ne uporabljate zanesljive kontracepcije;
If you are a woman of child bearing age read this page carefully
Ženske v rodni dobi naj skrbno preberejo to stran
If you are a woman of childbearing age you must use adequate contraception while taking, and for one month after stopping Zonisamide Mylan.
Če ste ženska v rodni dobi, morate uporabljati primerno obliko kontracepcije med zdravljenjem in še mesec dni po končanem zdravljenju z zdravilom Zonisamid Mylan.
If you are a woman of childbearing potential, you are advised not to become pregnant and to use adequate contraception while using Raptiva.
Če ste ženska v rodnem obdobju, vam svetujemo, da v času uporabe zdravila Raptiva ne zanosite in uporabljate zanesljivo kontracepcijo.
If you are a woman of childbearing potential, you are advised to avoid becoming pregnant while using Entyvio.
Ženskam v rodni dobi odsvetujemo zanositev med zdravljenjem z zdravilom Entyvio.
If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription as mycophenolate causes birth defects and miscarriage.
če ste bolnica, ki bi lahko bila noseča, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mikofenolat povzroči prirojene okvare in spontani splav,
If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription as mycophenolate causes birth defects and miscarriage.
če ste bolnica, ki bi lahko zanosila, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mikofenolat povzroči prirojene okvare in spontani splav,
if you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage.
če ste bolnica, ki bi lahko bila noseča, in pred prvim predpisanim receptom nimate potrjenega negativenega testa nosečnosti, saj lahko mikofenolat povzroči prirojene okvare in spontani splav,
If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage.
če ste bolnica, ki bi lahko zanosila, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mikofenolat povzroči prirojene okvare in spontani splav,
If you are a woman who could become pregnant you must always use two effective methods of contraception with CellCept.
Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom CellCept vedno uporabljati dve učinkoviti kontracepcijski zaščiti, in sicer: preden boste začeli jemati zdravilo CellCept, ves čas zdravljenja z zdravilom CellCept,
If you are a woman who could become pregnant you must always use two effective methods of contraception with Myclausen.
Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom Myclausen vedno uporabljati dve učinkoviti kontracepcijski zaščiti, in sicer: preden boste začeli jemati zdravilo Myclausen, ves čas zdravljenja z zdravilom Myclausen,
If you are a woman who could become pregnant you must always use two effective methods of contraception with Mycophenolate mofetil Teva.
Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom Mofetilmikofenolat Teva vedno uporabljati dve učinkoviti metodi kontracepcije: preden začnete jemati zdravilo Mofetilmikofenolat Teva; ves čas zdravljenja z zdravilom Mofetilmikofenolat Teva;
If you are a woman who could become pregnant you must always use two effective methods of contraception with Myfenax.
Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom Myfenax vedno uporabljati dve učinkoviti metodi kontracepcije: preden začnete jemati zdravilo Myfenax; ves čas zdravljenja z zdravilom Myfenax;
If you are a woman who could become pregnant you must use a reliable birth control method while you are taking Tafinlar and for 4 weeks after you stop taking it and for 4 months following the last dose of trametinib when given in combination with Tafinlar.
Če ste ženska, ki bi lahko zanosila, morate med jemanjem zdravila Tafinlar in še 4 tedne po koncu jemanja tega zdravila oziroma še 4 mesece po zadnjem odmerku trametiniba, če ga uporabljate v kombinaciji z zdravilom Tafinlar, uporabljati zanesljivo kontracepcijsko zaščito.
If you are a woman who could become pregnant you must use reliable contraception while you are taking Sivextro.
Če ste ženska, ki bi lahko zanosila, morate v obdobju jemanja zdravila Sivextro uporabljati zanesljivo kontracepcijo.
If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.
Če ste bolnica, ki bi lahko zanosila, morate pred začetkom zdravljenja zagotoviti negativen test nosečnosti in upoštevati nasvete za kontracepcijo, ki vam jih da vaš zdravnik.
If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.
Če ste bolnica, ki bi lahko zanosila, morate pred začetkom zdravljenja zagotoviti negativen test nosečnosti in upoštevati nasvete za kontracepcijo, ki vam jih daa vaš zdravnik.
If you are a woman who could become pregnant, you must use adequate birth control while you are being treated with KEYTRUDA and for at least 4 months after your last dose.
Če ste ženska v rodni dobi, morate med zdravljenjem z zdravilom KEYTRUDA in vsaj še 4 mesece po zadnjem odmerku tega zdravila uporabljati ustrezno kontracepcijo.
If you are a woman who could become pregnant, you must use reliable birth control (contraception) while you are taking Mekinist and for 4 months after you stop taking it.
Če ste ženska, ki bi lahko zanosila, morate med jemanjem zdravila Mekinist in še 4 mesece po koncu njegovega jemanja uporabljati zanesljivo kontracepcijsko zaščito.
If you are a woman who could become pregnant, you must use reliable contraception while you are taking Sivextro.
Če ste ženska, ki bi lahko zanosila, morate v obdobju zdravljenja z zdravilom Sivextro uporabljati zanesljivo kontracepcijo.
If you are a woman who could get pregnant during treatment with Emtricitabine/Tenofovir disoproxil Zentiva, you must use an effective method of contraception to avoid becoming pregnant.
Če ste ženska, ki bi lahko med zdravljenjem z zdravilom Emtricitabin/dizoproksiltenofovirat Zentiva zanosila, morate uporabljati učinkovito kontracepcijsko metodo, da bi s tem preprečili zanositev.
If you are a woman who could get pregnant during treatment with Truvada, you must use an effective method of contraception to avoid becoming pregnant.
Če ste ženska, ki bi lahko med zdravljenjem z zdravilom Truvada zanosila, morate uporabljati učinkovito kontracepcijsko metodo, da bi s tem preprečili zanositev.
If you are a woman who is breast-feeding, you must not take this medicine.
Če dojite, ne smete jemati tega zdravila.
If you are a woman who is pregnant or might get pregnant and are trying to open the capsules for your children or another patient unable to swallow, you should handle the contents with caution in order to avoid skin-eye contact or inhalation.
Če ste noseči ali bi lahko zanosili in odpirate kapsule za svoje otroke ali kakega drugega bolnika, ki ne more požirati, ravnajte pri odpiranju kapsule z vsebino pazljivo in se izogibajte stiku zdravila z očmi preko rok ali vdihavanju zdravila.
If you are a woman who is pregnant or might get pregnant and are trying to open the capsules, you should handle the contents with caution in order to avoid skin-eye contact or inhalation.
Če ste noseči ali bi lahko zanosili, ravnajte pri odpiranju kapsule z vsebino pazljivo in se izogibajte stiku zdravila z očmi preko rok ali vdihavanju zdravila.
If you are a woman with HIV it is recommended that you do not breast-feed, to avoid passing the virus to the baby in breast milk.
Če ste ženska, okužena z virusom HIV, je priporočljivo, da ne dojite, da s tem preprečite prenos virusa preko mleka na dojenčka.
If you are a woman with HIV or HBV do not breast-feed, to avoid passing the virus to the baby in breast milk.
Če ste ženska, okužena z virusom HIV ali HBV, ne dojite, da s tem preprečite prenos virusa preko mleka na dojenčka.
if you are a woman with:
če ste ženska in imate:
If you are a woman, you must not become pregnant during treatment and for several months afterwards.
Če ste ženska, ne smete zanositi med zdravljenjem in še nekaj mesecev po zaključku zdravljenja.
If you are a woman, you should continue to follow your doctor’s advice on cervical smear/Pap tests and preventative and protective measures.
Če ste ženska, morate še naprej upoštevati zdravnikova navodila o brisih materničnega vratu/testih Pap in preventivnih ter zaščitnih ukrepih.
If you are able to become pregnant, you must use birth control during treatment and for one month after stopping treatment.
Če bi lahko zanosili, morate med zdravljenjem in še en mesec po prenehanju zdravljenja uporabljati ustrezno kontracepcijo.
If you are able to become pregnant, your doctor will record with each prescription that the necessary measures, as outlined above, have been taken and will give you a record of this on your patient card or any other relevant documents.
Če lahko zanosite, bo vaš zdravnik ob vsakem receptu preveril, ali upoštevate zgoraj navedene nujne ukrepe in to potrdil na vaši kartici za bolnika ali drugih ustreznih dokumentih.
If you are able to become pregnant:
Če lahko zanosite:
If you are able to become pregnant: you must take precautions so that you do not become pregnant while taking Erivedge
Če obstaja možnost, da bi zanosili: morate upoštevati previdnostne ukrepe, da med jemanjem zdravila Erivedge ne boste zanosili.
If you are able to become pregnant: you must take precautions so that you do not become pregnant while taking Odomzo, you must use 2 methods of contraception, one highly effective method and one barrier method (see the examples below) while you are taking Odomzo, you must keep using this contraception for 20 months after you have stopped taking Odomzo because traces of the medicine remain in the body for a long time.
Če obstaja možnost, da bi zanosili: morate upoštevati previdnostne ukrepe, da ne bi zanosili v času jemanja zdravila Odomzo, morate v času jemanja zdravila Odomzo uporabljati 2 metodi kontracepcije, in sicer eno od zelo učinkovitih metod in eno od pregradnih metod (glejte primere spodaj), morate tako kontracepcijo uporabljati še 20 mesecev po tem, ko prenehate jemati zdravilo Odomzo, ker preostanek zdravila še dolgo ostane v telesu.